Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).

S Famulla; Thomas Pieber; J Eilbracht; D Neubacher; N Soleymanlou; HJ Woerle; UC Broedl; S Kaspers

doi:10.1089/dia.2016.0261

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).

S Famulla
, Thomas Pieber (First author)
, J Eilbracht
, D Neubacher
, N Soleymanlou
, HJ Woerle
, UC Broedl
, S Kaspers

Division of Endocrinology and Diabetology

Research output: Contribution to journal › Research article

45 Citations (Web of Science)

Original language	English
Journal	Diabetes Technology and Therapeutics
DOIs	https://doi.org/10.1089/dia.2016.0261
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Branches of science

301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine
304 Medical Biotechnology
305 Other Human Medicine, Health Sciences

Research Fields

Sustainable Health Research

DOI

10.1089/dia.2016.0261

Links

Cite this

Famulla, S., Pieber, T., Eilbracht, J., Neubacher, D., Soleymanlou, N., Woerle, HJ., Broedl, UC., & Kaspers, S. (2017). Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1). Diabetes Technology and Therapeutics. https://doi.org/10.1089/dia.2016.0261

@article{bdd4014175c24b408e846350077a5b31,

title = "Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).",

author = "S Famulla and Thomas Pieber and J Eilbracht and D Neubacher and N Soleymanlou and HJ Woerle and UC Broedl and S Kaspers",

year = "2017",

doi = "10.1089/dia.2016.0261",

language = "English",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "SAGE Publications Ltd",

}

Famulla, S, Pieber, T, Eilbracht, J, Neubacher, D, Soleymanlou, N, Woerle, HJ, Broedl, UC & Kaspers, S 2017, 'Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).', Diabetes Technology and Therapeutics. https://doi.org/10.1089/dia.2016.0261

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1). / Famulla, S; Pieber, Thomas (First author); Eilbracht, J et al.
In: Diabetes Technology and Therapeutics, 2017.

Research output: Contribution to journal › Research article

TY - JOUR

T1 - Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).

AU - Famulla, S

AU - Eilbracht, J

AU - Neubacher, D

AU - Soleymanlou, N

AU - Woerle, HJ

AU - Broedl, UC

AU - Kaspers, S

A2 - Pieber, Thomas

PY - 2017

Y1 - 2017

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000392822900009

UR - https://pubmed.ncbi.nlm.nih.gov/27929674

U2 - 10.1089/dia.2016.0261

DO - 10.1089/dia.2016.0261

M3 - Research article

C2 - 27929674

SN - 1520-9156

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

ER -